DAWN has 36-month beta value of -1.45. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DAWN is 59.28M, and currently, short sellers hold a 15.08% ratio of that float. The average trading volume of DAWN on May 08, 2024 was 1.06M shares.
DAWN) stock’s latest price update
Day One Biopharmaceuticals Inc (NASDAQ: DAWN)’s stock price has gone rise by 2.89 in comparison to its previous close of 16.60, however, the company has experienced a -0.12% decrease in its stock price over the last five trading days. GlobeNewsWire reported 2023-12-19 that BRISBANE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
DAWN’s Market Performance
Day One Biopharmaceuticals Inc (DAWN) has experienced a -0.12% fall in stock performance for the past week, with a 22.35% rise in the past month, and a 7.90% rise in the past quarter. The volatility ratio for the week is 6.24%, and the volatility levels for the past 30 days are at 7.90% for DAWN.. The simple moving average for the past 20 days is 10.70% for DAWN’s stock, with a 24.46% simple moving average for the past 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with Needham repeating the rating for DAWN by listing it as a “Buy.” The predicted price for DAWN in the upcoming period, according to Needham is $33 based on the research report published on April 24, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $9, previously predicting the price at $34. The rating they have provided for DAWN stocks is “Underperform” according to the report published on April 25th, 2023.
CapitalOne gave a rating of “Overweight” to DAWN, setting the target price at $40 in the report published on February 08th of the previous year.
DAWN Trading at 10.53% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -5.48% of loss for the given period.
Volatility was left at 7.90%, however, over the last 30 days, the volatility rate increased by 6.24%, as shares surge +18.78% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.14% upper at present.
During the last 5 trading sessions, DAWN fell by -0.12%, which changed the moving average for the period of 200-days by +41.16% in comparison to the 20-day moving average, which settled at $15.56. In addition, Day One Biopharmaceuticals Inc saw 16.99% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from Bender Jeremy, who sale 9,154 shares at the price of $17.85 back on May 03 ’24. After this action, Bender Jeremy now owns 642,602 shares of Day One Biopharmaceuticals Inc, valued at $163,417 using the latest closing price.
York Charles N II, the COO, CFO AND SECRETARY of Day One Biopharmaceuticals Inc, sale 8,078 shares at $17.85 during a trade that took place back on May 03 ’24, which means that York Charles N II is holding 217,293 shares at $144,214 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -405.31 for the present operating margin
- 0.16 for the gross margin
The net margin for Day One Biopharmaceuticals Inc stands at -373.1. The total capital return value is set at -0.76. Equity return is now at value -69.97, with -64.27 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -568.66. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -65.56.
Currently, EBITDA for the company is -205.68 million with net debt to EBITDA at 1.15. When we switch over and look at the enterprise to sales, we see a ratio of 2182.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.93.
Conclusion
To put it simply, Day One Biopharmaceuticals Inc (DAWN) has had a better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
